Skip To Main Content
Gerald Jingyue Li on Muck Rack

Gerald Jingyue Li

As seen in: The BMJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gerald Jingyue

Contact Gerald Jingyue, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer

|
By Gerald Jingyue Li, Ryon P. Graf, Julia C. F. Quintanilha
| The BMJ Verified
Introduction Tumor mutational burden (TMB) and PD-L1 immunohistochemistry are companion diagnostics used to guide immune checkpoint inhibitor (ICI) therapy use in the advanced non-small cell lung cancer (NSCLC) setting.1 As ICI use is expanding into the early-stage setting, biomarkers for stratifying responders and non-responders to ICI are needed.
Open in Who Shared Issue with article?

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness | JCO Precision Oncology

|
By Michael Storandt, Gerald Jingyue Li, Julia C.F. Quintanilha, Rachel Keller
| ascopubs.org
Your Privacy ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us. Because we respect your right to privacy, you can choose not to allow some or all types of cookies.
Open in Who Shared View Duplicates (124) Issue with article?

Quantifying the value of multi-gene testing in resected early-stage lung adenocarcinoma

|
By Kira Raskina, Katherine T. Lofgren, Gerald Jingyue Li, Bharathi Muthusamy
| jto.org
Abstract BACKGROUND Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICI), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multi-gene testing in early lung adenocarcinoma (LUAD).
Open in Who Shared Issue with article?
See all 4 articles